Results 141 to 150 of about 3,123 (163)
Dalbavancin in the treatment of different gram-positive infections: a real-life experience
International Journal of Antimicrobial Agents, 2018 Dalbavancin is a lipoglycopeptide with a very prolonged half-life enabling treatment with a single intravenous administration that has been approved to treat complicated skin and soft-tissue infections.
Patricia Carmen Muñoz García +2 more
exaly +2 more sources
French national cohort of first use of dalbavancin: A high proportion of off-label use [PDF]
International Journal of Antimicrobial Agents, 2019 Dalbavancin is a glycopeptide antibiotic with a long half-life, recently marketed in Europe for skin and soft tissue infections (SSTI), but real-life use is not well-known.
Alexandre Bleibtreu +2 more
exaly +2 more sources
Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres [PDF]
Clinical Microbiology and Infection, 2005 The activity of dalbavancin, a new semi-synthetic lipoglycopeptide antibiotic, was evaluated in comparison with other antibacterial agents against 1229 Gram-positive organisms collected from medical centres in Latin America.
Ana C. Gales, Ronald N Jones, R N Jones
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current trends in the real-life use of dalbavancin: report of a study panel
International Journal of Antimicrobial Agents, 2020Nicola Coppola +2 more
exaly